Rheumatoid Arthritis Clinical Trial
Official title:
A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase I/2a Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. for Moderate to Severe Rheumatoid Arthritis
Verified date | October 2022 |
Source | Kang Stem Biotech Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid arthritis
Status | Completed |
Enrollment | 33 |
Est. completion date | May 13, 2022 |
Est. primary completion date | October 5, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. of either gender, 19-80years old 2. Subjects must be diagnosed according to the 2010 ACR/EULAR criteria for at least 12 weeks duration. 3. Subjects must be diagnosed with ACR functional class I. II, III 4. = 6 tender joints, swollen joints (68 joint count) at Screening 5. Subject who has moderate to severe disease activity (DAS28-ESR>3.2) on screening visit 6. History of treatment for one of conventional DMARDs or biologic DMARDs or JAK inhibitors AND people diagnosed with either (a) or (b) by a trained person, or people that have potential side effects thus not qualified from using biologic DMARDs. 1. people that have no effect with permitted dose taking for more than 3 months 2. people with a history of side effects of relevant treatment 7. Subjects must be taking cDMARDs(including methotrexate, sulfasalazine, hydroxychloroquine, leflunomide) or tacrolimus of stable dose More than 12 weeks before baseline visit and be willing to remain on stable dose throughout the study 8. If subject is currently administering steroids everyday, when steroid dose is converted into prednisolone oral dose, the subject should take a stable dose(=10mg/day) over 4 weeks on screening visit 9. In case of taking NASAIDs, Tramadol patients with stable amount of medication at least 2 weeks before screening visit. 10. During screening visit , patients with an ESR result of 28mm/hr; patients with a 1.0mg/dL or greater in a CRP testing 11. Subject who understands and voluntarily sign an informed consent form Exclusion Criteria: 1. Subjects who is diagnosed ACR function class IV Rheumatoid Arthritis 2. Patients who are judged by the PI(or Sub-I) to be unable to participate in clinical trials due to uncontrolled or unstable cardiovascular disease or severe blood disease 3. Subjects who has AIDS, other rheumatic disease(Crohn's disease, systemic lupus erythematosus, lyme disease, psoriatic arthritis, spondylarthropathy, infectious or reactive arthritis, reiter's syndrome, etc.) 4. Prior use of bDMARDs, within the following windows prior to baseline - 24 weeks for Rituximab - 10 weeks for Abatacept, Golimumab, Certolizumab pegol, Tocilizumab - 7 weeks for Infliximab - 4 weeks for Etanercept - 3 weeks for Tofacitinib, Baricitinib 5. Subject who has history of hypersensitivity, heavy metal poisoning, etc. to drugs which is composed of similar components. 6. Subject who has treated intravenous, intramuscular steroid injection within 2 weeks before screening visit or intra-articular steroid injection within 4 weeks before screening visit 7. Subject who has administered ACTH(adrenocorticotropic hormone) agents within 4 weeks before screening visit 8. Subject who has undergone administration of any investigational drug within 30 days before screening visit. 9. Use of prohibited medication or inability to avoid the use of prohibited medication during the study 10. Pregnant, breast-feeding women 11. A female or male in their childbearing ages that is not willing to take proper contraceptive methods during a study 12. Subject who has sever dyshepatia (Serum creatinine level = 1.7mg/dl) 13. Subject who has severe renal dysfunction (ALT/AST/bilirubin value = 2 upper limit of the normal range at screening test) 14. Any other condition which the PI Judges would make patient unsuitable for study participation |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Chonnam National University Hospital | Gwangju | |
Korea, Republic of | Gangdong Kyung Hee University Hospital | Seoul | |
Korea, Republic of | Konkuk University Medical Center | Seoul | |
Korea, Republic of | Kyung Hee University Hospital | Seoul | |
Korea, Republic of | Seoul Hospital attached to Soonchunhyang University | Seoul | |
Korea, Republic of | Seoul national University Boramae | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Kang Stem Biotech Co., Ltd. |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety of FURESTEM-RA Inj. - number of adverse events | Evaluate the number of adverse events Safety of FURESTEM-RA Inj. | 4 weeks follow-up after treatment | |
Secondary | Efficacy as measured by ACR(American College of Rheumatology)20,50,70 reaction rate | 16 weeks follow-up after treatment | ||
Secondary | Efficacy as measured by EULAR (European League Against Rheumatism)reaction rate | 16 weeks follow-up after treatment | ||
Secondary | Efficacy as measured by DAS(Disease activity scores)28-ESR | DAS range is from = 3.2 (inactive) , >3.2 but = 5.1(moderate), >5.1(very active) | 16 weeks follow-up after treatment | |
Secondary | Efficacy as measured by KHAQ(Korean Health assessment questionnaire) | KHAQ range is from 0 (clear) to 60 (severe) | 16 weeks follow-up after treatment | |
Secondary | Efficacy as measured by CDAI (clinical disease activity index) | CDAI range is from 0 (clear) to 76 (severe) | 16 weeks follow-up after treatment | |
Secondary | Efficacy as measured by 100mm Pain VAS(Visual analogue scale) | 100mm Pain VAS range is from 0 (clear) to 100 (severe) | 16 weeks follow-up after treatment | |
Secondary | Total number of use and consumed amount of rescue medicine | 16 weeks follow-up after treatment | ||
Secondary | Change in Cytokine(TNF-a, Interleukin (IL)-1b, IL-4,IL-6,IL-8,IL-10,IL-13,IL-17A,IL-21,IL-22) | 16 weeks follow-up after treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |